New Phase 3 Data from ESC on Management of Uncontrolled or Treatment-Resistant Hypertension with an Aldosterone Synthase Inhibitor
New Phase 3 Data from ESC on Management of Uncontrolled or Treatment-Resistant Hypertension with an Aldosterone Synthase Inhibitor
Is There a Safe and Effective Anticoagulation Strategy for Secondary Prevention of Non-Cardioembolic Ischemic Stroke?
Non-Statin Cholesterol Management Update
Optimizing Care for HCM Patients: Evidence-Based, Pathology-Targeted Management for All
LIVE UPDATE FROM ACC25: More Support for the “Factor XI Hypothesis”
MANAGEMENT OF PSVT: UPDATE FROM ACC25
From PCP to Nephrologist & Supportive Patient Education to Achieve Continuity of Care and Adherence to Optimal Treatment Strategies in IgA Nephropathy
Unmet Needs in the Management of Atrial Fibrillation (AF)
LIVE UPDATE FROM AHA24: What do we know about antiplatelets added to anticoagulation in patients with AF?
Best Practices for Implementing Dual Endothelin Angiotensin Receptor Antagonist Therapeutics in Patients with IgAN
Update on Emerging Anticoagulants
IgAN Update Fall 2024
Update on Advanced Treatment Plans to Improve Outcomes for Patients with Primary Biliary Cholangitis
Best Practices for Implementing Dual Endothelin Angiotensin Receptor Antagonist Therapeutics in Patients with IgAN
Update From ESC24: New Data on Non-Statin Lipid Lowering Therapies and Reduced CV Risk
Venous Thromboembolism – Risk Assessment
A Scientific and Practical Guide to the Administration and Monitoring of FcRn Blockers for Generalized Myasthenia Gravis in the Infusion Center
A Scientific and Practical Guide to the Administration and Monitoring of FcRn Blockers for Generalized Myasthenia Gravis in the Infusion Center
Best Practices for Implementing Dual Endothelin Angiotensin Receptor Antagonist Therapeutics in Patients with IgAN